Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death

European Heart Journal

Volumn 26, Issue 19, 2005, Pages 2007-2012

  Straus, Sabine M J M ^a,b   Sturkenboom, Miriam C J M ^a   Bleumink, Gysèle S ^a,c   Dieleman, Jeanne P ^a   Van Der Lei, Johan ^a   De Graeff, Pieter A ^b,d   Kingma, Jan Herre ^c,d   Stricker, Bruno H Ch ^a,c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b MEDICINES EVALUATION BOARD   (Netherlands)

^c Inspectorate for Health Care   (Netherlands)

^d UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Non cardiac QTc prolonging drugs; Pharmaco epidemiology; Population based; Sudden cardiac death

Indexed keywords

CHLOROQUINE; CHLORPROMAZINE; CISAPRIDE; CLARITHROMYCIN; DOMPERIDONE; DROPERIDOL; ERYTHROMYCIN; HALOPERIDOL; LEVACETYLMETHADOL; MESORIDAZINE; PENTAMIDINE; PIMOZIDE; SPARFLOXACIN; THIORIDAZINE;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; DEATH; FEMALE; GENDER; GENERAL PRACTICE; HEART DEATH; HUMAN; INFORMATION SYSTEM; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MEDICAL RECORD; POPULATION; PRIORITY JOURNAL; QT PROLONGATION; RISK ASSESSMENT; SUDDEN DEATH; TIME SERIES ANALYSIS;

ADULT; AGED; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; CASE-CONTROL STUDIES; DEATH, SUDDEN, CARDIAC; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 26444560585     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehi312     Document Type: Article

References (39)

1. Priori SG, Aliot E, Blomstrom-Lundqvist C, Bossaert L, Breithardt G, Brugada P, Camm AJ, Capato R, Cobbe SM, Di Mario C, Maron BJ, McKenna WJ, Pedersen AK, Schwartz PJ, Trusz-Gluza M, Vardas P, Wellens HJ, Zipes DP. Task force on sudden cardiac death of the European Society of Cardiology. Eur Heart J 2001;22:1374-1450.
2. Myerburg RJ. Cardiac arrest and sudden cardiac death. In: Braunwald E, ed. Heart Disease, a Text Book of Cardiovascular Medicine. New York: WB Saunders Publishing Co., 1997. p742-779.
3. Chugh SS, Jui J, Gunson K, Stecker EC, John BT, Thompson B, Ilias N, Vickers C, Dogra V, Daya M, Krin J, Zhengh ZJ, Mensah G, McAnulty J. Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large U.S. community. J Am Coll Cardiol 2004;44:1268-1275.
4. Josephson M, Wellens HJ. Implantable defibrillators and sudden cardiac death. Circulation 2004;109:2685-2691.
5. Akar FG, Spragg DD, Tunin RS, Kass DA, Tomaselli GF. Mechanisms underlying conduction slowing and arrhythmogenesis in nonischemic dilated cardiomyopathy. Circ Res 2004;2:2.
6. Arking DE, Chugh SS, Chakravarti A, Spooner PM. Genomics in sudden cardiac death. Circ Res 2004;94:712-723.
7. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350:1013-1022.
8. Woosley RL. Drugs that prolong the QTc interval and/or induce Torsade de Pointes. http://www.qtdrugs.org/medical-pros/drug-lists/drug-lists.htm
9. CHMP/ICH/423/02. Note for guidance on the non clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. London: CHMP/ICH; 2004.
10. van der Lei J, Duisterhout JS, Westerhof HP, van der Does E, Cromme PV, Boon WM, vanBemmel JH. The introduction of computer-based patient records in The Netherlands. Ann Intern Med 1993;119:1036-1041.
11. Vlug AE, van der Lei J, Mosseveld BM, van Wijk MA, van der Linden PD, Sturkenboom MC, van Bemmel JH. Postmarketing surveillance based on electronic patient records: the IPCI project. Methods Inf Med 1999;38:339-344.
12. Lamberts H, Wood M, Hofmans-Okkes IM. International primary care classifications: the effect of fifteen years of evolution. Fam Pract 1992;9:330-339.
13. ATC index with DDDs. Oslo Norway: WHO collaborating Centre for Drug Statistics Methodology; 2002.
14. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999;17:151-183.
15. Greenland S. Modeling and variable selection in epidemiologic analysis. Am J Public Health 1989;79:340-349.
16. Hennekens CH, Buring JE. Epidemiology in Medicine. Philadelphia: Lippincott-Raven Publishers, 1987.
17. Straus SM, Bleumink GS, Dieleman JP, van der Lei J, Stricker BH, Sturkenboom MC. The incidence of sudden cardiac death in the general population. J Clin Epidemiol 2004;57:98-102.
18. Shah RR. Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing. Drug Saf 2004;27:145-172.
19. de Ponti F, Poluzzi E, Montanaro N. Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus. Eur J Clin Pharmacol 2001;57:185-209.
20. de Bruin ML, Hoes AW, Leufkens HG. QTc-prolonging drugs and hospitalizations for cardiac arrhythmias. Am J Cardiol 2003;91:59-62.
21. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003;58:32-45.
22. Walker AM, Szneke P, Weatherby LB, Dicker LW, Lanza LL, Loughlin JE, Yee CL, Dreyer NA. The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada. Am J Med 1999;107:356-362.
23. Drolet B, Rousseau G, Daleau P, Cardinal R, Turgeon J. Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders. Circulation 2000;102:1883-1885.
24. Shaffer D, Singer S, Korvick J, Honig P. Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System. Clin Infect Dis 2002;35:197-200.
25. Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004;351:1089-1096.
26. Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 2002;62:1649-1671.
27. Straus SM, Bleumink GS, Dieleman JP, van der Lei J, 't Jong GW, Kingma JH, Sturkenboom MC, Stricker BH. Antipsychotics and the risk of sudden cardiac death. Arch Intern Med 2004;164:1293-1297.
28. Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 2001;58:1161-1167.
29. Anderson ME, Al-Khatib SM, Roden DM, Califf RM. Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management. Am Heart J 2002;144:769-781.
30. Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C, Escande D, Franz M, Malik M, Moss A, Shah R. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur Heart J 2000;21:1216-1231.
31. Yang T, Roden DM. Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence. Circulation 1996;93:407-411.
32. Roden DM. QT bumps: unraveling the mechanisms. J Cardiovasc Electrophysiol 2001;12:1379-1380.
33. Khan IA. Clinical and therapeutic aspects of congenital and acquired long QT syndrome. Am J Med 2002;112:58-66.
34. Sheridan DJ. Drug-induced proarrhythmic effects: assessment of changes in QT interval. Br J Clin Pharmacol 2000;50:297-302.
35. Yap YG, Camm J. Risk of torsades de pointes with non-cardiac drugs. Doctors need to be aware that many drugs can cause QT prolongation. BMJ 2000;320:1158-1159.
36. Roden DM. Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. Pacing Clin Electrophysiol 1998;21:1029-1034.
37. Makita N, Horie M, Nakamura T, Ai T, Sasaki K, Yokoi H, Sakurai I, Otani H, Sawa H, Kitabatake A. Drug-induced long-QT syndrome associated with a subclinical SCN5A mutation. Circulation 2002;106:1269-1274.
38. Escande D. Pharmacogenetics of cardiac K(+) channels. Eur J Pharmacol 2000;410:281-287.
39. de Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI, van Ree JW, Daemen MJ, Houben LG, Wellens HJ. Out-of-hospital cardiac arrest in the 1990's: a population-based study in the Maastricht area on incidence, characteristics and survival. J Am Coll Cardiol 1997;30:1500-1505.